The mesenchymal stem cell industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.
While it may be possible to stay informed about mesenchymal stem cell industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant mesenchymal stem cell industry events for June 2015.
Mesenchymal Stem Cell News Round-Up for June 2015
-
A Cure for Osteoporosis, Scientists Develop Compound to Grow Mesenchymal Stem Cells
[June 16, 2015] The new compound, SR2595, which could substantially increase the osteoblasts (cells that secrete the substances for formation of bone), too held the potential for a number of therapies. This was owing to the fact that the compound acted on mesenchymal stem cells, which further had many therapeutic applications.
The scientists added that the suitability of testing the compound, SR2595, had been established in mice. Now, they wished to take their research towards the next stage and perform an extensive analysis of the compound’s efficiency in animal models of bone loss, aging, obesity and diabetes. -
FDA Approves Stemedica’s Phase 2a Alzheimer’s Therapy Study
[June 11, 2015] The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Stemedica Cell Technologies, Inc. The approval means that the company is allowed to initiate a phase 2a clinical study to evaluate the use of an allogeneic stem-cell therapy for the treatment of patients with mild to moderate dementia related to Alzheimer’s disease.
“We are very excited to take this next step in developing a treatment for this devastating disease,” stated the president and chief medical officer at Stemedica, Nikolai Tankovich, MD, PhD, who is also the executive chairman for Stemedica International. “Our upcoming Phase IIa clinical trial will enable us to make progress towards determining if our stem cell treatment may be able to halt or slow down the progression of Alzheimer’s disease and other forms of dementia.”
-
Gold nanoparticles with functional surfaces regulate osteogenic differentiation of stem cells
[June 8, 2015] Tissue Regeneration Materials Unit at the International Center for Materials Nanoarchitectonics (MANA) successfully developed gold nanoparticles that have functional surfaces and act on osteogenic differentiation of stem cells.In regenerative medicine, the technology to control stem cell functions such as differentiation and proliferation is indispensable. It has been reported that nanosized gold particles promote the differentiation of human mesenchymal stem cells into osteoblasts. Based on these reports, we assumed that gold nanoparticles with surface modified with functional groups is a promising candidate to control stem cell functions.
-
Ampio Pharma (AMPE) Announces Three Peer-Reviewed Ampion Publications on Knee Osteoarthritis
[June 9, 2015] Ampio Pharma (NYSE: AMPE) announced three peer-review publications that report the multifaceted and synergistic effects of Ampion™ in the treatment of osteoarthritis in the knee.
“Collectively, these three articles suggest that changing the major prostaglandins generated after an initial inflammatory response leads to the type of anti-inflammatory response seen clinically with LMWF5A-Ampion™. The first two research papers show that Ampion™ elicits all of the biochemical changes needed for the synthesis of an anti-inflammatory prostaglandin. They also demonstrate the biochemical changes in mesenchymal stem cells (the precursors of chondrocytes and osteocytes) induced by Ampion™, all of which suggest that treatment by Ampion™ could lead to the replenishment of cartilage in this disease.”
-
Paracrine Action of Mesenchymal Stem Cells Revealed by Single Cell Gene Profiling in Infarcted Murine Hearts
[June 4, 2015] Mesenchymal stem cells (MSCs) have been recently demonstrated as a promising stem cell type to rescue damaged myocardium after acute infarction. One of the most important mechanisms underlying their therapeutic effects is the secretion of paracrine factors. However, the expression profile of paracrine factors of MSCs in infarcted hearts, especially at single cell level, is poorly defined.
Our study, for the first time, elucidated gene expression profiles, as well as regulation of paracrine factors, of MSCs at single cell level in vivo, indicating that paracrine factors from MSCs account for the improvement of cardiac function after infarction.
-
Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas
[June 2015] Pediatric brainstem glioma is an incurable malignancy because of its inoperability. As a result of their extensive tropism toward cancer and the possibility of autologous transplantation, human adipose-derived mesenchymal stem cells (hAT-MSC) are attractive vehicles to deliver therapeutic genes to brainstem gliomas. In this study, in a good manufacturing practice (GMP) facility, we established clinically applicable hAT-MSCs expressing therapeutic genes and investigated their therapeutic efficacy against brainstem glioma in mice.
The results indicate that non-viral transient single sTRAIL gene transfer to autologous hAT-MSCs is a clinically applicable stem cell-based gene therapy for brainstem gliomas in terms of therapeutic effects and safety.
-
Mesenchymal Stem Cell Therapy Could Reduce Damaging Inflammation in Cystic Fibrosis
[June 2, 2015] Studies have shown that MSCs have a great ability to suppress chemicals and cells in the immune system that lead to inflammation. Because of this, many researchers are now investigating the potential for MSCs to modulate this inflammatory environment and reduce damage and scarring seen in inflamed organs.
If this therapeutic target evolves into application for CF patients, inflammatory damage seen in the lungs, pancreases, and other tissues could be slowed and could reduce the possibility of lung transplant and cystic fibrosis related diabetes (CFRD). Another promising aspect is the cell source, with bone marrow serving as a donor source to culture these MSCs for patient use.
To learn more about opportunities for commercializing MSCs, view the global strategic report “Mesenchymal Stem Cells – Advances & Applications” now.
Future Posts about the Stem Cell Industry
To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time. No spam ever, just great stuff.
About Us
BioInformant is the only research firm that has served the cord blood sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine (CIRM).
